Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Kulbe JR, Hall ED.

Prog Neurobiol. 2017 Nov;158:15-44. doi: 10.1016/j.pneurobio.2017.08.003. Epub 2017 Aug 26. Review.

PMID:
28851546
2.

Protein astrogliopathies in human neurodegenerative diseases and aging.

Kovacs GG, Lee VM, Trojanowski JQ.

Brain Pathol. 2017 Sep;27(5):675-690. doi: 10.1111/bpa.12536.

PMID:
28805003
3.

Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Reilly P, Winston CN, Baron KR, Trejo M, Rockenstein EM, Akers JC, Kfoury N, Diamond M, Masliah E, Rissman RA, Yuan SH.

Neurobiol Dis. 2017 Oct;106:222-234. doi: 10.1016/j.nbd.2017.06.005. Epub 2017 Jun 10.

PMID:
28610892
4.

Tau physiology and pathomechanisms in frontotemporal lobar degeneration.

Bodea LG, Eckert A, Ittner LM, Piguet O, Götz J.

J Neurochem. 2016 Aug;138 Suppl 1:71-94. doi: 10.1111/jnc.13600. Epub 2016 Jun 15. Review.

5.

Glial Tau Pathology in Tauopathies: Functional Consequences.

Kahlson MA, Colodner KJ.

J Exp Neurosci. 2016 Feb 10;9(Suppl 2):43-50. doi: 10.4137/JEN.S25515. eCollection 2015. Review.

6.

Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies.

Sud R, Geller ET, Schellenberg GD.

Mol Ther Nucleic Acids. 2014 Jul 29;3:e180. doi: 10.1038/mtna.2014.30.

7.

What Renders TAU Toxic.

Götz J, Xia D, Leinenga G, Chew YL, Nicholas H.

Front Neurol. 2013 Jun 10;4:72. doi: 10.3389/fneur.2013.00072. eCollection 2013.

8.

CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.

Bendlin BB, Carlsson CM, Johnson SC, Zetterberg H, Blennow K, Willette AA, Okonkwo OC, Sodhi A, Ries ML, Birdsill AC, Alexander AL, Rowley HA, Puglielli L, Asthana S, Sager MA.

PLoS One. 2012;7(6):e37720. doi: 10.1371/journal.pone.0037720. Epub 2012 Jun 6.

9.

Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation.

Rissman RA, Staup MA, Lee AR, Justice NJ, Rice KC, Vale W, Sawchenko PE.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6277-82. doi: 10.1073/pnas.1203140109. Epub 2012 Mar 26.

10.

Tau-targeted treatment strategies in Alzheimer's disease.

Götz J, Ittner A, Ittner LM.

Br J Pharmacol. 2012 Mar;165(5):1246-59. doi: 10.1111/j.1476-5381.2011.01713.x. Review.

11.

Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Khandelwal PJ, Dumanis SB, Herman AM, Rebeck GW, Moussa CE.

Mol Cell Neurosci. 2012 Jan;49(1):44-53. doi: 10.1016/j.mcn.2011.09.002. Epub 2011 Sep 14.

12.

In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders.

Maeda J, Zhang MR, Okauchi T, Ji B, Ono M, Hattori S, Kumata K, Iwata N, Saido TC, Trojanowski JQ, Lee VM, Staufenbiel M, Tomiyama T, Mori H, Fukumura T, Suhara T, Higuchi M.

J Neurosci. 2011 Mar 23;31(12):4720-30. doi: 10.1523/JNEUROSCI.3076-10.2011.

13.

The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases.

Khandelwal PJ, Moussa CE.

Front Psychiatry. 2010 Jun 3;1:15. doi: 10.3389/fpsyt.2010.00015. eCollection 2010.

14.

Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Ando K, Leroy K, Héraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP.

Am J Pathol. 2011 Feb;178(2):803-16. doi: 10.1016/j.ajpath.2010.10.034.

15.

Structural abnormalities in the cortex of the rTg4510 mouse model of tauopathy: a light and electron microscopy study.

Ludvigson AE, Luebke JI, Lewis J, Peters A.

Brain Struct Funct. 2011 Mar;216(1):31-42. doi: 10.1007/s00429-010-0295-4. Epub 2010 Dec 9.

16.

Neuronal models for studying tau pathology.

Koechling T, Lim F, Hernandez F, Avila J.

Int J Alzheimers Dis. 2010 Jul 19;2010. pii: 528474. doi: 10.4061/2010/528474.

17.

Tau as a biomarker of neurodegenerative diseases.

Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, Caillet-Boudin ML, Pasquier F, Maurage CA, Sablonnière B, Vanmechelen E, Buée L.

Biomark Med. 2008 Aug;2(4):363-84. doi: 10.2217/17520363.2.4.363.

18.

Vaccination as a therapeutic approach to Alzheimer's disease.

Wisniewski T, Boutajangout A.

Mt Sinai J Med. 2010 Jan-Feb;77(1):17-31. doi: 10.1002/msj.20156. Review.

19.

Knock-out and transgenic mouse models of tauopathies.

Denk F, Wade-Martins R.

Neurobiol Aging. 2009 Jan;30(1):1-13. Epub 2007 Jun 22. Review.

20.

Cortical neuronal and glial pathology in TgTauP301L transgenic mice: neuronal degeneration, memory disturbance, and phenotypic variation.

Murakami T, Paitel E, Kawarabayashi T, Ikeda M, Chishti MA, Janus C, Matsubara E, Sasaki A, Kawarai T, Phinney AL, Harigaya Y, Horne P, Egashira N, Mishima K, Hanna A, Yang J, Iwasaki K, Takahashi M, Fujiwara M, Ishiguro K, Bergeron C, Carlson GA, Abe K, Westaway D, St George-Hyslop P, Shoji M.

Am J Pathol. 2006 Oct;169(4):1365-75.

Supplemental Content

Support Center